Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis

Circulation Research

Volumn 84, Issue 5, 1999, Pages 489-497

  Schmidt, Ann Marie ^a   Yan, Shi Du ^a   Wautier, Jean Luc ^b   Stern, David ^a  

^a College of Physicians and Surgeons ^*  (United States)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Amyloid; Diabetes; Glycoxidation; Inflammation; Nuclear factor B

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMYLOID BETA PROTEIN; HEMOGLOBIN A1C; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGAND;

AMYLOIDOSIS; ATHEROSCLEROSIS; BRAIN BLOOD VESSEL; CELL ACTIVATION; CELL INTERACTION; DIABETIC ANGIOPATHY; DISEASE ASSOCIATION; GENETIC MANIPULATION; GLYCATION; HYPERGLYCEMIA; KIDNEY FAILURE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; SHORT SURVEY; SIGNAL TRANSDUCTION; VASCULAR DISEASE;

EID: 0344286498     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.84.5.489     Document Type: Short Survey

References (89)

1. Gimbrone MA, Nagel T, Topper JN. Biomechanical activation: an emerging paradigm in endothelial adhesion biology. J Clin Invest. 1997; 100:S61-S65.
2. Pober JS, Cotran RC. Cytokines and endothelial cell biology. Physiol Rev. 1990;70:427-451.
3. Mantovani A, Bussolino F, Dejana E. Cytokine regulation of endothelial cell function. FASEB J. 1992;6:2591-2599.
4. Nakashima Y, Plump A, Raines E, Breslow J, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb. 1994;141:133-140.
5. Linton M, Farese R, Hobbs H, Young S. Transgenic mice expressing high plasma concentrations of human apoB100 and Lp(a). J Clin Invest. 1993;92:3029-3037.
6. Purcell-Huynh D, Farese R, Linton M, Sanan D, Young S. Transgenic mice expressing high levels of human apoB develop severe atherosclerotic lesions in response to a high-fat diet. J Clin Invest. 1995;95: 2246-2257.
7. Ishibashi S, Goldstein J, Brown M, Herz J, Burns D. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein-negative mice. J Clin Invest. 1995;95:2246-2257.
8. Uusitupa M, Niskanen L, Siitonen O, Voutilainen E, Pyorala K. Five-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation. 1990;82:27-36.
9. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. J Am Med Assoc. 1979;241:2035-2038.
10. King G, Brownlee M. The cellular and molecular mechanisms of diabetic complications. Endocrinol Metab Clin North Am. 1996;25:255-270.
11. Bierman E. Geroge Lyman Duff Memorial Lecture: atherogenesis in diabetes. Arterioscler Thromb. 1992;12:647-656.
12. Krolewski A, Kosinski E, Warram J, Leland O, Busick E, Asmal A, Rand A, Christlieb A, Bradley R, Kahn C. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol. 1987;59:750-755.
13. Greene D, Lattimer S, Sima A. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med. 1987;316:599-606.
14. Inoguchi T, Xia P, Kunisaki M, Higashi S, Feener E, King G. Insulin's effect on protein kinase C and diacylglycerol induced by diabetes and glucose in vascular tissues. Am J Physiol. 1994;267:E369-E379.
15. Xia P, Inoguchi T, Kern T, Engerman R, Oates P, King G. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hyperglactosemia. Diabetes 1994;43:1122-1129.
16. Ishii H, Jirousek M, Koya D, Takagi C, Xia P, Clermont A, Bursell S-E, Kern T, Ballas L, Heath W, Stramm L, Feener E, King G. Amelioration of vascular dysfunction in diabetic rats by an oral PKC beta inhibitor. Science. 1996;272:728-731.
17. Brownlee M. Advanced glycosylation in diabetes and aging. Annu Rev Med. 1995;46:223-234.
18. Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. J Clin Invest. 1994;94:110-117.
19. Ruderman N, Williamson J, Brownlee M. Glucose and diabetic vascular disease. FASEB J. 1992;6:2905-2914.
20. Sell D, Monnier VM. Structure elucidation of senescence cross-link from human extracellular matrix: implication of pentoses in the aging process. J Biol Chem. 1989;264:21597-21602.
21. Dyer D, Dunn J, Thorpe S, Bailie K, Lyons T, McCance D, Baynes J. Accumulation of Maillard products in skin collagen in diabetes and aging. J Clin Invest. 1993;91:2463-2469.
22. Giardino I, Edelstein D, Brownlee M. BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. J Clin Invest 1996;97: 1422-1428.
23. Baynes J. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991;40:405-412.
24. Miyata S, Monnier VM. Immunohistochemical detection of AGEs in diabetic tissues using monoclonal antibody to pyrraline. J Clin Invest 1992;89:1102-1112.
25. Schleicher E, Wagner E, Nerlich A. Increased accumulation of glycoxidation product carboxymethyllysine in human tissues in diabetes and aging. J Clin Invest. 1997;99:457-468.
26. Ikeda K, Higashi T, Sano H, Jinnouchi Y, Yoshida M, Araki T, Ueda S, Horiuchi S. Carboxymethyllysine protein adduct is a major immunological epitope in proteins modified with AGEs of the Maillard reaction. Biochemistry. 1996;35:8075-8083.
27. Reddy S, Bichler J, Wells-Knecht K, Thorpe S, Baynes J. Carboxymethyllysine is a dominant AGE antigen in tissue proteins. Biochemistry. 1995;34:10872-10878.
28. Palinski W, Koschinsky T, Butler S, Miller E, Vlassara H, Cerami A, Witztum J. Immunological presence of AGEs in atherosclerotic lesions of euglycemic rabbits. Atheroscler Thromb Vasc Biol. 1995;15:571-582.
29. Horie K, Miyata T, Maeda K, Miyata S, Sugiyama, Sakai H, van Ypersele de Strihou C, Monnier VM, Witztum JL, Kurokawa K. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. J Clin Invest 1997;100: 2995-3004.
30. Rosenfeld M, Palinski W, Herttula S, Butler S, Witztum J. Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis. 1990;10:336-349.
31. Smith MA, Taneda S, Richey P, Miyata S, Yan SD, Stern D, Sayre LM, Monnier VM, Perry G. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci U S A. 1994;91:5710-5714.
32. Takedo A, Yasuda T, Miyata T, Mizuno K, Li M, Yoneyama S, Horie K, Maeda K, Sobue G. Immunohistochemical study of advanced glycation end products in aging and Alzheimer's disease brain. Neurosci Lett 1996;221:17-20.
33. Dyer D, Blackledge S, Thorpe S, Baynes J. Formation of pentosidine during nonenzymatic browning of protein by glucose: identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem. 1991;266:11654-11660.
34. Grandhee S, Monnier VM. Mechanisms of formation of the Maillard protein crosslink pentosidine: ribose, glucose, fructose and ascorbate as pentosidine precursors. J Biol Chem. 1991;266:11649-11653.
35. Beisswenger P, Moore L, Brinck-Johnsen T, Curphey T. Increased collagen-linked pentosidine levels and AGEs in early diabetic nephropathy. J Clin Invest. 1993;92:212-217.
36. Sell D, Lapolla A, Odetti P, Fogarty J, Monnier VM. Pentosidine formation in skin correlates with severity of complications in individuals with longstanding IDDM. Diabetes. 1992;41:1286-1292.
37. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern DM. Cellular receptors for AGEs. Arterioscler Thromb. 1994;14:1521-1528.
38. Semenkovich C, Heinecke JW. The mystery of diabetes and atherosclerosis. Diabetes. 1997;46:327-334.
39. Dunn J, Ahmed M, Murtiashaw M, Richardson J, Walla M, Thorpe S, Baynes J. Reaction of ascorbate with lysine and protein under autoxidizing conditions: formation of CML by reaction between lysine and products of autoxidation of ascorbate. Biochemistry 1990;29:10964-10970.
40. Drueke T. Beta-2-microglobulin amyloidosis and renal bone disease. Miner Electrolyte Metab. 1991;17:261-272.
41. Kock K. Dialysis-related amyloidosis. Kidney Int. 1992;41:1416-1429.
42. Miyata T, Oda O, Inagi R, Iida Y, Araki N, Yamada N, Horiuchi S, Taniguchi N, Maeda K, Kinoshita T. Beta-2-microglobulin modified with AGEs is a major component of hemodialysis-associated amyloidosis. J Clin Invest. 1993;92:1243-1252.
43. Miyata T, Hori O, Zhang J, Yan SD, Ferran L, Iida Y, Schmidt AM. RAGE mediates the interaction of AGE-beta-2-microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway: implications for the pathogenesis of dialysis-related amyloidosis. J Clin Invest 1996;98:1088-1094.
44. Yan SD, Yan SF, Chen X, Fu J, Chen M, Kuppusamy P, Smith M, Perry G, Godman G, Nawroth P, Zweier J, Stern DM. Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid β-peptide. Nat Med. 1995;1:693-699.
45. Yan SD, Chen X, Schmidt AM, Brett J, Godman G, Zou YS, Scott C, Caputo C, Frappier T, Smith M, Perry G, Yen S-H, Stern DM. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci USA. 1994;91:7787-7791.
46. Vitek M, Bhattacharya K, Vlassara H, Bucala R, Manogue K, Cerami A. AGEs contribute to amyloidosis in Alzheimer's disease. Proc Natl Acad Sci USA. 1994;91:4766-4770.
47. Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, Hori O, Stern D, Schmidt AM. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest. 1996;97:238-243.
48. Schmidt AM, Hori O, Chen J-X, Li J-F, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D. Advanced glycation endproducts interacting with their endothelial receptor induce expression of VCAM-1 in cultured human endothelial cells and in mice. J Clin Invest. 1995;96:1395-1403.
49. Esposito C, Gerlach H, Brett J, Stern D, Vlassara H. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med. 1989;170:1387-1407.
50. Vlassara H, Bucala R, Striker L. Pathogenic effects of AGEs: biochemical, biologic and clinical implications for diabetes and aging. Lab Invest. 1994;70:138-151.
51. Bucala R, Tracey K, Cerami A. AGEs quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest. 1991;87:432-438.
52. Schmidt AM, Yan SD, Stern DM. The dark side of glucose. Nat Med. 1995;1:1002-1004.
53. Khoury J, Thomas C, Loike J, Hickman S, Cao L, Silverstein S. Macrophages adhere to glucose-modified basement membrane via their scavenger receptors. J Biol Chem. 1994;269:10197-10200.
54. Vlassara H, Li Y, Imani F, Wojciechowicz D, Yang Z, Liu F, Cerami A. Galectin-2 as a high affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med. 1995;1:634-646.
55. Suzuki H, Kurihara Y, Takeya M, Kamada N, Kataoka M, Jishage K, Ueda O, Sakaguchi H, Higashi T, Suzuki T, Takashima Y, Kawabe Y, Cynshi O, Wada Y, Honda M, Kurihara H, Aburatani H, Doi T, Matsumoto A, Azuma S, Noda T, Toyoda Y, Itakura H, Yazaki Y, Kodama T, et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature. 1997;386:292-296.
56. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, Esposito C, Hegarty H, Hurley W, Clauss M, Wang F, Pan YC, Tsang TC, Stern DM. Isolation and characterization of binding proteins for advanced glycosylation end products from lung tissue which are present on the endothelial cell surface. J Biol Chem. 1992;267:14987-14997.
57. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern DM, Shaw A. Cloning and expression of RAGE: a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992;267:14998-15004.
58. Sugaya K, Fukagawa T, Matsumoto K-I, Mita K, Takahashi E-I, Ando A, Inoko H, Ikemura T. Three genes in the human MHC class III region near the junction with class II: gene for RAGE, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-2. Genomics. 1994;23:408-419.
59. Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE. J Biol Chem. 1997;272:16498-16506.
60. Hori O, Brett J, Nagashima M, Nitecki D, Morser J, Stern DM, Schmidt AM. RAGE is a cellular binding site for amphoterin: mediation of neurite outgrowth and co-expression of RAGE and amphoterin in the developing nervous system. J Biol Chem. 1995;270:25752-25761.
61. Brett J, Schmidt AM, Zou YS, Yan SD, Weidman E, Pinsky DJ, Neeper M, Przysiecki M, Shaw A, Migheli A, Stern DM. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol. 1993;143:1699-1712.
62. Ritthaler U, Roth H, Bierhaus A, Ziegler R, Schmidt AM, Waldherr R, Wahl P, Stern D, Nawroth P. Expression of RAGE in peripheral occlusive vascular disease. Am J Pathol. 1995;146:688-694.
63. Rauvala H, Merenmies J, Pihlaskari R, Korkolainen M, Huhtala J, Panula P. The adhesive and neurite-promoting molecule p30: analysis of the amino terminal sequence and production of antipeptide antibodies that detect p30 at the surface of neuroblastoma cells and of brain neurons. J Cell Biol. 1987;107:2293-2305.
64. Rauvala H, Pihlaskari R. Isolation and some characteristics of an adhesive factor of brain that enhances neurite outgrowth in central neurons. J Biol Chem. 1987;262:16625-16635.
65. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature. 1996;382:685-691.
66. Yan SD, Zhu H, Fu J, Yan SF, Roher A, Tourtellotte WW, Rajavashisth T, Chen X, Godman GC, Stern D, Schmidt AM. Amyloid beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci USA. 1997;94: 5296-5301.
67. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D. Enhanced cellular oxidant stress by the interaction of AGEs with their receptors/binding proteins. J Biol Chem. 1994;269:9889-9897.
68. Viberti G. Increased capillary permeability in diabetes mellitus and its relationship to microvascular angiopathy. Am J Med. 1983;146:688-694.
69. Mattock M, Morrish N, Viberti G, Keen H, Fitzgerald A, Jackson G. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes. 1992;41:736-741.
70. Feldt-Rasmussen B. Increased transcapillary escape rate of albumin type I diabetic patients with microalbuminuria. Diabetologia. 1996;29: 282-286.
71. Nannipieri M, Rizzo L, Rapuano A, Pilo A, Penno G, Navalesi R. Increased transcapillary escape rate of albumin in a microalbuminuric type II diabetic subject. Diabetes Care. 1995;18:1-9.
72. Stehouwer C, Nauta J, Zeldenrust G, Hackeng W, Doner A, Ottolander G. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet. 1992;340: 319-323.
73. Williamson J, Chang K, Tilton R, Prater C, Jeffrey J, Weigel C, Sherman W. Increased vascular permeability in spontaneously diabetic BB/W rats and in rats with mild versus severe streptozotocin-induced diabetes. Diabetes. 1987;36:813-821.
74. Nordestgaard B, Stender S, Kjeldsen K. Reduced atherogenesis in cholesterol-fed diabetic rabbits: giant lipoproteins do not enter the arterial wall. Arteriosclerosis. 1988;8:421-428.
75. Kunjathoor V, Wilson D, LeBoeuf R. Increased atherosclerosis in streptozotocin-induced diabetic mice. J Clin Invest. 1996;97:1767-1773.
76. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow W-S. Stem D, Schmidt AM. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med. 1998;4: 1025-1031.
77. Palinski W, Herttula S, Rosenfeld M, Butler S. Socher S, Parthasarathy S, Curtiss L, Witztum J. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis. 1990;10:325-335.
78. Raman K, Tsai M, Lu Y, Fan L, Lindenberg N, Stern D, Berglund L, Huang L-S. Genetically diabetic (db/db) transgenic mice overexpressing human apoB exhibit accelerated atherosclerosis. Circulation 1998; 98(suppl I):I-465.
79. Makker G, Fan L, Lindenberg N, Lu Y, Wu Q, Lee K, Stern D, Schmidt AM. Suppression of accelerated atherosclerosis in diabetic LDL receptor null mice by sRAGE. Circulation 1998;98(suppl I):I-310.
80. Lander H, Tauras J, Ogiste J, Moss R, Schmidt AM. Activation of RAGE triggers a MAP kinase pathway regulated by oxidant stress. J Biol Chem. 1997;272:17810-17814.
81. Fu C, Pischetsrieder M, Hofmann M, Yan SF, Stem D, Schmidt AM. Carboxymethyl-lysine (CML) advanced glycation endproduct (AGE) modifications of proteins are ligands for RAGE that activate cell signalling pathways. Circulation. 1998;98(suppl I):I-315. Abstract 1651.
82. Taki H, Kashiwagi A, Nishio Y, Kikkawa R, Horiike K. Existence of oxidative stress and alteration of antioxidative enzymes in aorta of streptozotocin-induced diabetic rats. J Jpn Diabetes Soc. 1997;40: 99-107.
83. Nishio Y, Kashiwagi A, Taki H, Shinozaki K, Maeno Y, Kojima H, Maegawa H, Masakazu H, Hidaka H, Yasuda H, Horiike K, Kikkawa R. Altered activities of transcription factors and their related gene expression in cardiac tissues of diabetic rats. Diabetes. 1998;47:1318-1325.
84. Richardson M, Hadcock S, Dereske M, Cybulsky M. Increased expression in vivo of VCAM-1 and E-selectin by the aortic endothelium of normolipemic and hyperlipemic diabetic rabbits. Arterioscler Thromb. 1994;14:760-769.
85. Collins T. Endothelial nuclear factor kB and the initiation of the atherosclerotic lesion. Lab Invest. 1993;68:499-508.
86. Neish A, Williams A, Palmer H, Whitley M, Collins T. Functional analysis of the human VCAM-1 promoter. J Exp Med. 1992;176: 1583-1593.
87. Schmidt AM, Crandall J, Hori O, Cao R, Lakatta E. Elevated plasma levels of VCAM-1 in diabetic patients with microalbuminuria: a marker of vascular dysfunction and progressive vascular disease. Br J Haematol. 1996;92:747-750.
88. Otsuki M, Hashimoto K, Morimoto Y, Kishimoto T, Kasayama S. Circulating VCAM-1 in atherosclerotic NIDDM patients. Diabetes. 1997; 46:2096-2101.
89. Hofmann M, Drury S, Fu C, Li J, Qu X, Qu W, Schmidt AM. EN-RAGE (extracellular novel-RAGE binding protein) activates endothelial cells and macrophages to mediate inflammatory responses. Circulation. 1998; 98(suppl I):I-316. Abstract 1657.